Pluvicto®▼ is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.1
LUTATHERA® is indicated for the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.2
The RLT Hub is your guide to understanding GEP-NETs, PSMA-positive mCRPC and RLT
The RLT Hub was developed by Novartis Pharmaceuticals UK Ltd, for UK healthcare professionals only. The platform provides information on RLT and the management of eligible patients with NET and the management of eligible patients with PSMA-positive mCRPC.
Site features
This site provides you with the relevant information and resources to guide your knowledge and understanding of GEP-NET, PSMA-positive mCRPC and RLT.
AR, androgen receptor; GEP, gastroenteropancreatic; mCRPC, metastatic castration-resistant prostate cancer; NET, neuroendocrine tumour; PSMA, prostate-specific membrane antigen; RLT, radioligand therapy.
References
- Pluvicto® (lutetium [177Lu] vipivotide tetraxetan) Summary of Product Characteristics.
- LUTATHERA® (lutetium [177Lu] oxodotreotide) Summary of Product Characteristics.